Experienced Health Economist with strong HTA and market access experience at both the UK and Global level. Work across a range of disease areas, including immunology, diabetes, oncology and virology. Focussed and organised, with extensive project management skills. In-depth knowledge of UK reimbursement pathways, as well as strong familiarity with international markets e.g. Canada, Germany, Republic of Ireland, France and Italy. Current responsibilities encompass strategic and technical support for global HTA deliverables, HTA submissions, cost-effectiveness and budget impact models and market access strategy, as well as mentoring of team members.

I am passionate about Market Access and translating clinical evidence to the requirements of different healthcare systems and helping patients to get access to innovative treatment options. I have gathered 20 years of experience on local and global level and my special interest is on healthcare environment changes such as European Pharma Legislation, EU HTA or IRA. My sound medical background as a doctor, strong analytic capabilities and a university education in health business administration are the foundation for a holistic and integrative approach in this complex environment. I am a passionate leader, dedicated to a modern, team-focused and choaching leadership style with a strong focus on diversity and development of my teams.

Responsible for running of the overall practice of Ansea, a healthcare consulting firm, specialising in Market Access, Stakeholder Engagement & Commercial Planning for pharma, bio-pharma and medical devices.

Leading the regulatory and R&D policy activities globally, setting up strategy and operations for policy, mentoring and coaching the trade representatives, ensuring executive communication, supporting development decisions with policy and regulatory science analysis, building thought leadership, advocating for brain health priorities.

At medac group, we believe that health is humanity’s most valuable resource. Since 1970, our mission has been to improve patients’ quality of life worldwide by making the best medical treatments available. As a globally operating pharmaceutical company headquartered in Germany, we provide high-quality medical treatments for patients worldwide in 91 countries. With more than 2.000 employees we are committed to improving human health.   All our products are manufactured in Germany and other European countries to the highest standards, utilizing our own logistics center and production sites, and subsequently distributed worldwide.  

At UCB, we put our heart, soul and skills into making a difference for people living with severe diseases. We look to transform patients’ lives by pushing the boundaries of what is possible. With us, our talents makes the most of who they are, unlocking innovation and setting new standards for patients. Everything we do starts with a simple question: “How will this make a difference to the lives of people living with severe diseases?” And to find the answers, we connect globally with patients and their families living with the physical and social burdens of severe disease. These connections give us new perspectives, drive our innovation, and offer a hope for a new generation of therapies that will help to transform lives.

At Bayer, we’re committed to driving sustainable development and generate a positive impact with our businesses. Through the power of science, we’re pioneering new possibilities that advance life for all of us. That means reimagining how we care for ourselves and one another by empowering everyday health, improving approaches to patient care, and finding better ways to nourish our communities around the world.

ANSEA is a global healthcare consulting firm that enables pharmaceuticals, biopharmaceuticals and medical device companies navigate through complex healthcare systems across the world and helps patients in getting access to their innovative solutions.

Lundbeck is a global pharmaceutical company solely focused on neuroscience. We cover the full value chain, from molecule to patient, in this rapidly evolving area of treatment. For more than 70 years we have maintained our focus on neuroscience. Our legacy and commitment to breakthrough innovation provide the foundation for developing truly transformative treatments for neuro-rare and neuro-specialty conditions. We are 5,600 employees in more than 50 countries, and our products are available in more than 100 countries. We have research facilities in Denmark and the United States, and our production facilities are located in Denmark, France, and Italy.